01494-A: Identifying the cause of drug resistance in canine lymphoma
Grant Status: Closed
This study was being conducted at the Louisiana State University School of Veterinary Medicine. Unfortunately we were only able to enroll 9 cases to date. Additionally, many of the dogs enrolled have not progressed with their cancer in a normal fashion. However, after analysis of the data to date, we have found that the levels of p-glycoprotein in blood lymphocytes throughout the chemotherapy protocol are not reflective of remission status or response to therapy. In fact, there is quite a high degree of variability in the samples obtained. However, many of the dogs also had high levels at the start of the protocol (at diagnosis). Additionally, we have had only two dogs finish the entire CHOP protocol. This has made drawing any further conclusions very difficult. However, the one dog that has had the longest survival and is still alive at over 18 months had much lower values of P-glycoprotein at diagnosis than the other dogs. There is reason to support that the levels of p-glycoprotein at the time of diagnosis could be reflective of long term survival in patients undergoing a CHOP based protocol for lymphoma. An abstract presented at ACVIM in 2002 found that functional assays of p-gp may provide useful information in dogs with lymphoma. Currently, there are no papers evaluating the levels of p-glycoprotein at the time of diagnosis in lymphoma patients. Although, it is only one dog, we feel that a study evaluating the levels of p-glycoprotein at the time of diagnosis by flow cytometry may be beneficial in predicting long term survivors of lymphoma.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.